Motus GI (NASDAQ:MOTS) vs. InspireMD (NYSE:NSPR) Head to Head Comparison

InspireMD (NYSE:NSPR) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Earnings and Valuation

This table compares InspireMD and Motus GI”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$7.78 million	8.93	-$19.92 million	($0.84)	-1.95
Motus GI	$319,000.00	0.00	-$12.87 million	($14.69)	0.00

Motus GI has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InspireMD and Motus GI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Motus GI	N/A	N/A	N/A

Risk & Volatility

InspireMD has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for InspireMD and Motus GI, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	2	0	3.00
Motus GI	0	0	0	0	0.00

InspireMD currently has a consensus target price of $5.00, indicating a potential upside of 204.88%. Given InspireMD’s stronger consensus rating and higher probable upside, equities analysts clearly believe InspireMD is more favorable than Motus GI.

Insider and Institutional Ownership

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 20.1% of Motus GI shares are owned by institutional investors. 34.1% of InspireMD shares are owned by company insiders. Comparatively, 0.3% of Motus GI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

InspireMD beats Motus GI on 8 of the 14 factors compared between the two stocks.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.